Alcresta Revenue and Competitors
Estimated Revenue & Valuation
- Alcresta's estimated annual revenue is currently $17.1M per year.
- Alcresta's estimated revenue per employee is $213,350
Employee Data
- Alcresta has 80 Employees.
- Alcresta grew their employee count by 38% last year.
Alcresta's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Chief Operating Officer | Reveal Email/Phone |
3 | SVP Medical Affairs | Reveal Email/Phone |
4 | VP | Reveal Email/Phone |
5 | VP Research and New Product Development | Reveal Email/Phone |
6 | Chief Commercial Officer | Reveal Email/Phone |
7 | Senior Director | Reveal Email/Phone |
8 | Associate Director, Regulatory Affairs | Reveal Email/Phone |
9 | Director Marketing | Reveal Email/Phone |
10 | Sr Regional Business Director - Rare Genetic Disease at Agios Pharmaceuticals | Reveal Email/Phone |
Alcresta Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $9.8M | 36 | 13% | N/A | N/A |
#2 | $8.5M | 36 | 29% | N/A | N/A |
#3 | $3M | 12 | -29% | N/A | N/A |
#4 | $5630M | 7477 | -11% | $450M | N/A |
#5 | $4.5M | 14 | 0% | N/A | N/A |
#6 | $7.2M | 59 | 28% | $29.6M | N/A |
#7 | $14.3M | 13 | -72% | N/A | N/A |
#8 | $2.3M | 31 | 94% | $44M | N/A |
#9 | $40.7M | 145 | 9% | N/A | N/A |
#10 | $45.7M | 149 | 0% | N/A | N/A |
What Is Alcresta?
Alcresta Therapeutics is dedicated to developing and commercializing novel, enzyme-based products designed to address challenges faced by people living with gastrointestinal disorders and rare diseases. The company uses its proprietary technology platform to support a broad pipeline of products, with an initial focus on pancreatic insufficiency or fat malabsorption, which results in malabsorption common in cystic fibrosis, digestive cancers, preterm birth, and other serious diseases. The company's lead product, RELiZORB®, is designed to reliably and efficiently deliver the optimal nutritional and caloric benefit from existing enteral feeding formulas by improving the breakdown and absorption of fats, in particular long-chain polyunsaturated fatty acids like omega-3 (including DHA, EPA). RELiZORB is indicated for use in pediatric patients (ages 5 years and above) and adult patients to hydrolyze fats in enteral formula. The company's platform is supported by our extensive experience in pharmaceutical, medical device and nutritional product development. Based in Massachusetts, the company is backed by top-tier venture investors Athyrium Capital Management, Bessemer Venture Partners, Frazier Healthcare, and Third Rock Ventures.
keywords:N/AN/A
Total Funding
80
Number of Employees
$17.1M
Revenue (est)
38%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Alcresta News
Alcresta announced its first profitable year in 2021, the completion of royalty payments to the Cystic Fibrosis Foundation (CFF) and a doubling...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $16.7M | 81 | 5% | N/A |
#2 | $23.5M | 81 | -10% | N/A |
#3 | $25.1M | 81 | -2% | N/A |
#4 | $13.1M | 81 | -7% | N/A |
#5 | $17.3M | 82 | 39% | N/A |